Eric Hsu
Corporate Officer/Principal en INMED PHARMACEUTICALS INC. .
Fortuna: 15 $ al 31/05/2024
Cargos activos de Eric Hsu
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| INMED PHARMACEUTICALS INC. | Corporate Officer/Principal | 13/03/2018 | - |
Historial de carrera de Eric Hsu
Antiguos cargos conocidos de Eric Hsu.
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
enGene, Inc.
 enGene, Inc. BiotechnologyHealth Technology enGene, Inc. develops therapeutic solutions for the treatment of metabolic diseases. It operates as a biotechnology company which develops a mucosal immunotherapy platform for treating several prevalent, chronic diseases including inflammatory bowel disease and diabetes. The firm also develops proprietary, non-integrating biopolymer based nucleotide DNA and siRNA delivery technology that facilitates localized delivery of immune-modulating proteins to the intestinal mucosa for treating various immune disorders. The company was founded in 1999 by Anthony T. Cheung, John C. Brown, Timothy J. Kieffer, and Francis John Gargiulo and is headquartered in Vancouver, Canada. | Director de Operaciones | 01/01/2002 | 01/01/2018 |
| Director Técnico/Científico/I+D | 01/01/2002 | 01/01/2018 |
Formación de Eric Hsu.
| McGill University | Undergraduate Degree |
| University of Toronto | Doctorate Degree |
Estadísticas
Internacional
| Canadá | 5 |
Operativa
| Chief Operating Officer | 1 |
| Chief Tech/Sci/R&D Officer | 1 |
| Undergraduate Degree | 1 |
Sectorial
| Health Technology | 3 |
| Consumer Services | 3 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| INMED PHARMACEUTICALS INC. | Health Technology |
| Empresas privadas | 1 |
|---|---|
enGene, Inc.
enGene, Inc. BiotechnologyHealth Technology enGene, Inc. develops therapeutic solutions for the treatment of metabolic diseases. It operates as a biotechnology company which develops a mucosal immunotherapy platform for treating several prevalent, chronic diseases including inflammatory bowel disease and diabetes. The firm also develops proprietary, non-integrating biopolymer based nucleotide DNA and siRNA delivery technology that facilitates localized delivery of immune-modulating proteins to the intestinal mucosa for treating various immune disorders. The company was founded in 1999 by Anthony T. Cheung, John C. Brown, Timothy J. Kieffer, and Francis John Gargiulo and is headquartered in Vancouver, Canada. | Health Technology |
- Bolsa de valores
- Insiders
- Eric Hsu
- Experiencia
